Abstract
The GINA 2019 report introduces revolutionary changes in the pharmacotherapy of asthma in children > 5 years old, adolescents and adults. For safety reasons, experts from the GINA 2019 report no longer recommend the use of short-acting b2-agonists (SABA) as monotherapy, but in combination with inhaled corticosteroid (ICS). In all adults and children ≥ 12 years of age, the preferred control treatment is ICS in a dose dependent on asthma symptoms or ICS with formoterol in the SMART/MART regimen (maintenance and rescue therapy from the same inhaler). The alternative is ICS with long-acting b2-agonist in “rigid” dosing and SABA “as needed”. The optimal treatment method for the vast majority of asthmatics aged ≥ 12 years is currently SMART/MART therapy, which most effectively prevents asthma exacerbations. It can be carried out using budesonide with formoterol from dry powder inhalers (Easyhaler®, Turbuhaler® and Spiromax®) or beclometasone with formoterol from a pressurised metered dose inhaler.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
